Supplier
NPI deactivated
Associated Pain Specialists, PC
Associated Pain Specialists, PC was paid $6.83M by Medicaid between Jan 2018 and Dec 2024, across 91 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 37% of everything it billed.
33Billing provider infoASSOCIATED PAIN SPECIALISTS, PC
KNOXVILLE, TN 37909
KNOXVILLE, TN 37909
33aNPI1487075099assigned 12/27/2013
33bProvider typeDurable Medical Equipment & Medical Supplies
28Total paid$6.83M
24GClaims331,153
24DCodes billed91
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Durable Medical Equipment & Medical Supplies providers in Tennessee
Rank by total paid#11 of 296
Median peer was paid$15K
This provider vs. median443×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 33,955 | $893K | |
| 2019 | 27,650 | $797K | |
| 2020 | 27,130 | $851K | |
| 2021 | 37,187 | $881K | |
| 2022 | 53,604 | $972K | |
| 2023 | 79,801 | $1.22M | |
| 2024incomplete | 71,826 | $1.22M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 37% | 86,028 | 73,783 | $2.51M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 9.5% | 17,793 | 14,887 | $647K |
| J3300 | Injection, triamcinolone acetonide, preservative free, 1 mg | 8.0% | 7,126 | 3,334 | $545K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 7.9% | 29,746 | 25,977 | $537K |
| 96132 | 4.8% | 16,878 | 15,580 | $326K | |
| 96130 | 4.2% | 16,854 | 15,564 | $289K | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.1% | 10,732 | 9,452 | $210K |
| 64635 | 3.0% | 1,326 | 889 | $206K | |
| 64493 | 1.9% | 1,709 | 1,328 | $130K | |
| 80305 | 1.6% | 15,516 | 13,342 | $112K | |
| 62323 | 1.4% | 1,227 | 1,007 | $97K | |
| L0650 | Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf | 1.3% | 221 | 178 | $91K |
79 more codes
| 96138 | 1.3% | 16,905 | $87K | |
| 64636 | 1.2% | 1,467 | $79K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.1% | 1,562 | $75K |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | 1.1% | 16,889 | $74K |
| 27096 | <1% | 489 | $67K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,265 | $64K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 724 | $57K |
| 93923 | <1% | 1,509 | $54K | |
| 20552 | <1% | 2,884 | $52K | |
| 64494 | <1% | 1,517 | $49K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 962 | $33K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 1,017 | $33K |
| 20610 | <1% | 1,130 | $32K | |
| 83970 | <1% | 1,972 | $27K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,422 | $20K |
| 82670 | <1% | 2,036 | $19K | |
| 95923 | <1% | 522 | $17K | |
| 64483 | <1% | 185 | $15K | |
| 82627 | <1% | 2,174 | $15K | |
| 84270 | <1% | 1,971 | $13K | |
| 95924 | <1% | 575 | $13K | |
| 83001 | <1% | 1,979 | $12K | |
| 83002 | <1% | 1,976 | $12K | |
| 20611 | <1% | 376 | $12K | |
| 83003 | <1% | 1,969 | $11K | |
| 84481 | <1% | 2,005 | $11K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,965 | $11K |
| 82607 | <1% | 2,013 | $10K | |
| 81025 | <1% | 2,587 | $9K | |
| 82746 | <1% | 2,006 | $9K | |
| 82728 | <1% | 1,939 | $8K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 2,220 | $8K |
| 64495 | <1% | 327 | $8K | |
| 80053 | Comprehensive metabolic panel | <1% | 2,782 | $8K |
| 77002 | <1% | 279 | $7K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 944 | $6K |
| 83550 | <1% | 2,156 | $6K | |
| 84439 | <1% | 1,988 | $6K | |
| 82962 | <1% | 4,634 | $6K | |
| 83735 | <1% | 2,219 | $5K | |
| 84146 | <1% | 745 | $5K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,917 | $5K |
| 83540 | <1% | 2,176 | $4K | |
| 64490 | <1% | 49 | $4K | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 2,007 | $4K |
| 83615 | <1% | 2,204 | $4K | |
| 86431 | <1% | 2,412 | $4K | |
| 82043 | <1% | 2,087 | $4K | |
| 11043 | <1% | 67 | $4K | |
| 86140 | <1% | 2,412 | $4K | |
| 62321 | <1% | 44 | $3K | |
| 83690 | <1% | 2,195 | $3K | |
| 84100 | <1% | 2,199 | $3K | |
| 93040 | <1% | 738 | $3K | |
| 64633 | <1% | 14 | $3K | |
| 82150 | <1% | 2,191 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 474 | $3K |
| L0180 | Cervical, multiple post collar, occipital/mandibular supports, adjustable | <1% | 18 | $2K |
| 36416 | <1% | 2,235 | $2K | |
| 99442 | <1% | 216 | $2K | |
| 99406 | <1% | 383 | $2K | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 813 | $2K |
| 64491 | <1% | 45 | $1K | |
| 99441 | <1% | 77 | $870.67 | |
| 64450 | <1% | 39 | $834.81 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 942 | $720.39 |
| 72110 | <1% | 64 | $696.34 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 55 | $692.24 |
| 72114 | <1% | 25 | $429.84 | |
| 72170 | <1% | 77 | $379.51 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 351 | $228.14 |
| 64492 | <1% | 13 | $197.96 | |
| 84403 | <1% | 18 | $129.97 | |
| 84402 | <1% | 18 | $126.14 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 20 | $88.70 |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 48 | $75.42 |
| 72100 | <1% | 25 | $73.74 | |
| 84153 | <1% | 19 | $71.58 | |
| J3302 | Injection, triamcinolone diacetate, per 5 mg | 0% | 24 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialODELL, ROBERT (SECRETARY)
| Provider | Location | Paid |
|---|---|---|
| Robert Odell MD PHD Medical Enterprises | Las Vegas, NV | $152K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.